AOD-9604vsCagriSema

AOD-9604 is a modified fragment of human growth hormone comprising amino acids 176-191 with an additional tyrosine residue at the N-terminus. This specific region of the GH molecule contains the lipolytic (fat-burning) domain while lacking the receptor binding regions responsible for growth-promoting and diabetogenic effects. The result is a peptide that mimics the fat metabolism effects of growth hormone without stimulating IGF-1 production, bone growth, or insulin resistance.

The primary mechanism involves stimulation of beta-3 adrenergic receptors on adipocytes, which activates hormone-sensitive lipase (HSL) through a cAMP-dependent pathway. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, which are then released into the bloodstream for oxidation by muscle and liver tissue. Simultaneously, AOD-9604 appears to inhibit lipogenesis — the synthesis of new fatty acids from non-lipid precursors — by downregulating acetyl-CoA carboxylase and fatty acid synthase activity in adipocytes.

Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor or stimulate JAK2/STAT5 signaling, which is why it avoids the IGF-1 elevation, water retention, and insulin resistance associated with exogenous GH use. However, it should be noted that AOD-9604 failed to show significant weight loss compared to placebo in Phase II/III clinical trials, raising questions about whether its in vitro lipolytic activity translates to meaningful clinical effects at the doses tested.

CagriSema exploits the principle that the brain's appetite regulation system has multiple independent signaling pathways, and targeting two of them simultaneously produces weight loss greater than either alone. The semaglutide component activates GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, suppressing hunger through POMC neuron activation and NPY/AgRP neuron inhibition, while also slowing gastric emptying and improving glycemic control.

The cagrilintide component activates amylin receptors (CTR/RAMP complexes) in the area postrema and lateral parabrachial nucleus — brain regions that form a parallel but distinct satiety circuit. Amylin receptor signaling reduces meal size by promoting early satiation, whereas GLP-1 signaling primarily reduces between-meal hunger and food cravings. Together, they address both the desire to eat and the amount consumed per meal.

At the metabolic level, both components enhance insulin secretion and suppress glucagon in a glucose-dependent manner, but through separate pancreatic receptor populations. The combination also produces synergistic effects on gastric emptying, further reducing postprandial glucose spikes. Phase 3 trial data showed approximately 25% body weight loss — among the highest recorded for any pharmaceutical intervention — with the combination significantly outperforming either component alone, validating the dual-pathway hypothesis.